Tego Science. Inc.
KKRX:1914206,920.00
KRW
-100.00
(-1.42%)
ISIN
KR7191420009
Return %
Stock
S&P 500
1Y
-59.65
14.39
3Y
-10.36
81.42
5Y
-70.92
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Sae-Wha Jeon
- Full Time Employees
- 40
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Seoul South Korea
- IPO Date
- Nov 6, 2014
- Website
- tegoscience.com
- Similar Companies
- Business
- Tego Science, Inc. is a South Korea-based biotechnology and regenerative medicine company that develops, manufactures, and commercializes cell therapy products, three-dimensional tissue models, and bioactive cosmeceuticals. Founded in 2001 and headquartered in Seoul, South Korea, the company operates across the biopharmaceutical, medical device, and aesthetic healthcare sectors, providing advanced therapeutic solutions for wound management, tissue regeneration, and non-animal efficacy and safety testing. The company's core product and service portfolio comprises autologous and allogeneic cell therapies, including Holoderm, an autologous cultured epidermal sheet therapy indicated for the treatment of severe deep second- and third-degree burns; Kaloderm, an allogeneic cultured keratinocyte sheet therapy approved for the treatment of diabetic foot ulcers and deep second-degree burns; and Rosmir, an autologous dermal fibroblast therapy indicated for aesthetic correction and the improvement of prominent facial wrinkles and nasolabial folds. In the testing and screening segment, the company manufactures Neoderm, a comprehensive family of three-dimensional reconstructed human tissue models—including epidermis, dermis, full-thickness skin, and mucosal models—utilized by pharmaceutical, chemical, and cosmetics companies as alternatives to animal testing for toxicity, irritation, and efficacy assessments. Additionally, Tego Science develops and commercializes advanced skincare and cosmeceutical formulations incorporating cell culture-derived conditioned media and bioactive peptides, while offering specialized Contract Development and Manufacturing Organization (CDMO) services, cell storage, and custom tissue engineering solutions to domestic and international healthcare clients. In recent strategic developments, Tego Science has expanded its regenerative pipeline beyond dermatological indications into orthopedic therapeutics, advancing its lead clinical programs TPX-114 (autologous fibroblast cell therapy) and TPX-115 (allogeneic fibroblast cell therapy) for the treatment of partial-thickness rotator cuff tears and tendinopathies. The company has also accelerated international commercialization initiatives, pursuing cross-border distribution partnerships and regulatory pathways in key Asian and Western markets for Kaloderm and the Neoderm testing platform in response to growing global demand for animal-free testing alternatives. Furthermore, Tego Science has expanded its CDMO business infrastructure and optimized its Good Manufacturing Practice (GMP) production facilities to support third-party cell therapy biomanufacturing contracts and bolster domestic and overseas commercial supply chains.